Please login to the form below

Not currently logged in
Email:
Password:

Dicerna appoints chief financial officer

Jack Green to take on the role on a permanent basis

Dicerna Jack GreenUS biopharmaceutical firm Dicerna has appointed Jack Green as its chief financial officer.

Green has been serving as the company's interim chief financial officer since January this year and will now take on the role on a permanent basis.

Dr Douglas Fambrough, Dicerna's president and chief executive, said: “I am very pleased to announce Jack as permanent CFO, as he brings to Dicerna a wealth of knowledge in finance and a strong track-record with public biotech companies.

“Since joining the company as interim CFO, Jack's strategic and business insights have added tremendous value and will be instrumental to the continued growth of Dicerna.”

Green has over 30 years of financial management experience, over twenty of which he gained in the biotechnology sector.

He has served as the chief financial officer of GTC Biotherapeutics and Verastem, as well as vice president, finance of On-Q-ity, a US biotechnology company.

Green said: “Dicerna has made great progress developing an exciting pipeline of clinical-stage oncology and rare disease product candidates as well as an emerging pipeline of DsiRNA-EX conjugate programmes for liver-targeted diseases.

“I look forward to contributing to Dicerna's success as we advance these programmes through clinical development and to working closely with the management team and board of directors.”

25th April 2016

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials
As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...

Infographics